Trump administration authorizes CIA for covert action in Venezuela - Bloomberg
Amid Bicara Therapeutics Inc’s (NASDAQ:BCAX) impressive 75% surge over the past six months, Chief Financial Officer Hyep Ivan sold 6,415 shares of common stock on October 9, 2025, at prices ranging from $18.15 to $18.41, for a total value of $116,931. The $996 million market cap company’s stock currently trades near overbought levels, according to InvestingPro technical indicators.
According to a Form 4 filing with the Securities and Exchange Commission, the same day, Ivan also exercised options to acquire 6,415 shares of Bicara Therapeutics at a price of $3.7898, for a total value of $24,311.
In other recent news, Bicara Therapeutics has been the subject of several analyst updates and ratings. TD Cowen has reiterated its Buy rating on Bicara Therapeutics, citing the recent $8 billion acquisition of Merus by Genmab as validation for the emerging class of EGFR bispecific antibodies, a field in which Bicara is also active. Jones Trading has initiated coverage on Bicara with a Buy rating and a price target of $22.00, highlighting the company’s promising bispecific antibody treatment for head and neck cancer. H.C. Wainwright, while maintaining a Buy rating, has slightly lowered its price target to $40.00 due to higher projected long-term operating expenses. Piper Sandler has also initiated coverage with an Overweight rating and a $36.00 price target, pointing to a "substantial disconnect" between market perception and the views of key opinion leaders regarding Bicara’s ficera treatment. These developments reflect a continued interest and confidence in Bicara Therapeutics’ potential within the biopharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.